Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on June 5, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy, the addition of adjuvant regional nodal irradiation does not reduce the risk for invasive breast cancer recurrence or death, according to a study published in the June 5 issue of the New England Journal of Medicine.

Eleftherios P. Mamounas, M.D., from the AdventHealth Cancer Institute in Orlando, Florida, and colleagues examined whether regional nodal irradiation improves outcomes in patients with biopsy-proven, node-positive breast cancer who reach ypN0 status after neoadjuvant chemotherapy. Participants with T1 to T3, N1, M0 breast cancer who achieved ypN0 status were randomly assigned to receive regional nodal irradiation or no regional nodal irradiation (772 and 784 individuals, respectively). The interval of freedom from invasive breast cancer recurrence or death from breast cancer was examined as the primary end point.

The researchers found 109 primary end point events after a median follow-up of 59.5 months (50 events in the irradiation group and 59 events in the no-irradiation group). There was no significant increase in the invasive breast cancer recurrence-free interval in the regional nodal irradiation group. Point estimates of survival free from the primary end-point events were 92.7 and 91.8 percent in the irradiation and no-irradiation groups, respectively. No increase in the locoregional recurrence-free interval, distant recurrence-free interval, disease-free survival, or overall survival was seen with regional nodal irradiation. There were no deaths related to protocol-specific therapy, nor were there unexpected adverse events.

"The results of our trial indicate that patients with positive axillary lymph nodes who reach stage ypN0 after neoadjuvant chemotherapy have low rates of disease recurrence and do not receive a statistically significant benefit from regional nodal irradiation at five years," the authors write. "These results support a shift in treatment strategy in that regional nodal irradiation can be tailored in patients treated with neoadjuvant chemotherapy on the basis of their pathological nodal response."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords